What Are GLP-1 Medications?

What Are GLP-1 Medications?

GLP-1 medications are a class of prescription drugs that mimic glucagon-like peptide-1, a hormone your small intestine releases after you eat. They lower blood sugar by stimulating insulin release, reduce appetite by acting on hunger centers in the brain, and slow how fast food leaves the stomach. In clinical trials, the strongest option (tirzepatide) produced an average weight loss of 22.5% of body weight over 72 weeks; the highest-potency GLP-1-only drug (semaglutide 2.4 mg) produced 16.9%. As of April 2026, eleven are FDA-approved in the United States, treating type 2 diabetes, chronic obesity, cardiovascular risk, obstructive sleep apnea, or some combination.

How GLP-1 Medications Work

GLP-1 itself is an incretin hormone — a short-acting signal your gut sends when food arrives. Natural GLP-1 breaks down in minutes. GLP-1 receptor agonists are engineered to survive in the body for hours to days, extending the hormone's four core effects:

• Insulin secretion, glucose-dependent. The pancreas releases insulin only when blood sugar is elevated, which is why GLP-1 drugs rarely cause hypoglycemia on their own.
• Glucagon suppression. GLP-1 blocks the hormone that tells the liver to dump stored glucose, flattening post-meal sugar spikes.
• Slowed gastric emptying. Food stays in the stomach longer, which smooths blood sugar and extends fullness after meals.
• Central appetite reduction. GLP-1 receptors in the hypothalamus reduce hunger signaling, and patients often describe a quieter "food noise" within days of starting.

A newer generation of drugs — tirzepatide (Mounjaro, Zepbound) — adds a second hormone receptor (GIP) to the GLP-1 mechanism. In head-to-head trials, this dual agonist produced meaningfully greater weight loss than GLP-1-only medications.

The FDA-Approved GLP-1 Medications

Eleven drugs are currently FDA-approved in the United States. They differ in their active ingredient, delivery (injection vs tablet), dosing frequency, and what conditions they are officially approved to treat.

| Brand | Generic | Class | Route | Frequency | Primary Use | | --- | --- | --- | --- | --- | --- | | Ozempic | semaglutide | GLP-1 | injection | weekly | type 2 diabetes | | Wegovy | semaglutide | GLP-1 | injection and oral | weekly (inj) / daily (oral) | chronic weight management, CV risk | | Rybelsus | semaglutide | GLP-1 | oral | daily | type 2 diabetes | | Mounjaro | tirzepatide | dual GIP/GLP-1 | injection | weekly | type 2 diabetes | | Zepbound | tirzepatide | dual GIP/GLP-1 | injection | weekly | chronic weight management, sleep apnea | | Foundayo | orforglipron | GLP-1 | oral | daily | chronic weight management | | Trulicity | dulaglutide | GLP-1 | injection | weekly | type 2 diabetes | | Saxenda | liraglutide | GLP-1 | injection | daily | chronic weight management | | Victoza | liraglutide | GLP-1 | injection | daily | type 2 diabetes | | Byetta | exenatide | GLP-1 | injection | twice daily | type 2 diabetes | | Bydureon | exenatide | GLP-1 | injection | weekly | type 2 diabetes |

Three drugs share active ingredients with others. Ozempic and Wegovy are both semaglutide, at different doses and for different indications. Mounjaro and Zepbound are both tirzepatide, similarly differentiated. Victoza and Saxenda are both liraglutide. The choice between sibling drugs usually comes down to what condition you have and which one your insurance covers.

Who Qualifies for a GLP-1 Medication?

Eligibility depends on which drug and which indication. In general:

• Type 2 diabetes. Ozempic, Trulicity, Mounjaro, Victoza, Rybelsus, Byetta, and Bydureon are FDA-approved for adults with type 2 diabetes as an adjunct to diet and exercise. Most guidelines (including the American Diabetes Association) now recommend GLP-1 drugs early in treatment, especially for patients with established cardiovascular disease or chronic kidney disease.
• Chronic weight management. Wegovy, Zepbound, Saxenda, and Foundayo are approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea. Wegovy is also approved for adolescents age 12+ at the 95th BMI percentile, and Zepbound is additionally approved for moderate-to-severe OSA in adults with obesity.
• Cardiovascular risk reduction. Wegovy received a separate FDA indication in March 2024 for reducing heart attacks, strokes, and cardiovascular death in adults with established cardiovascular disease who also have overweight or obesity.

GLP-1 drugs are generally not appropriate for anyone with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2 (MEN 2), or a known hypersensitivity to the active ingredient. They carry a boxed warning for thyroid C-cell tumors based on rodent studies.

Single vs. Dual Agonists — A Meaningful Difference

The clinical field has been split into two generations. First-generation GLP-1-only drugs (Ozempic, Wegovy, Trulicity, Victoza, Saxenda, Byetta, Bydureon, Rybelsus) target a single receptor. Second-generation dual GIP/GLP-1 drugs (Mounjaro, Zepbound) target two.

In the SURMOUNT-5 trial, published in May 2025, tirzepatide produced roughly 50% more weight loss than semaglutide at their respective maximum weight-management doses. That gap is the headline reason most clinicians now consider Zepbound the most potent approved option for chronic weight management. Oral orforglipron (Foundayo), approved in April 2026, is a third architecture — a small molecule rather than a peptide — and offers the potency of the newer injectables in daily tablet form, though at lower peak weight loss (about 12.4% in the ATTAIN-1 trial) than tirzepatide.

The direct comparisons most people ask about:

• Mounjaro vs Ozempic — dual agonist vs GLP-1-only for type 2 diabetes
• Wegovy vs Zepbound — head-to-head for weight management
• Semaglutide vs Tirzepatide — the two active ingredients, regardless of brand
• Orforglipron vs Wegovy — oral vs injection, both approved for obesity

Injectable vs. Oral — What Changes in Practice

For most of the last decade, every potent GLP-1 drug required a weekly or daily injection. That has started to shift. Three oral options are now available:

• Rybelsus (semaglutide, 2019 approval) — daily tablet for type 2 diabetes. Lower absorption than injected semaglutide, so weight-loss effect is modest.
• Oral Wegovy (semaglutide, December 2025 approval) — daily 25 mg tablet for chronic weight management. In the OASIS 4 trial, produced about 16.6% weight loss — similar to the injection.
• Foundayo (orforglipron, April 2026 approval) — daily tablet using a small-molecule GLP-1 agonist. Easier to manufacture at scale than peptide injections.

Tablets lower the psychological barrier for patients who fear needles, improve travel convenience, and open supply-chain headroom that injections have struggled to match. Injections remain the standard for peak efficacy. See oral vs injectable GLP-1 for the full trade-off.

What to Expect: Side Effects, Timeline, and Cost

Side effects are primarily gastrointestinal — nausea is the most common in every pivotal trial, with rates between 12% and 44% depending on the drug and dose. Most side effects are mild, concentrated during dose titration, and fade over weeks. The titration schedule — starting low and increasing every four weeks — exists specifically to limit GI tolerability problems. Serious adverse events are rare but include pancreatitis, gallbladder events, and (theoretical in humans) thyroid C-cell tumors.

Timeline. Patients typically see appetite reduction within days, early weight loss within 4–8 weeks, and most of the trial-reported weight loss over 12–18 months. A1C reductions in diabetes patients are usually visible at the first three-month check-up.

Cost. Without insurance, brand-name GLP-1 drugs list between roughly $900 and $1,350 per month in the U.S. Manufacturer savings cards, self-pay programs (LillyDirect, NovoCare), and insurance coverage all meaningfully reduce that. Coverage for weight-management indications remains inconsistent and is changing quickly.

How to Choose the Right GLP-1

No GLP-1 is uniformly best — the right choice depends on your condition, your insurance, and what side effects you tolerate. A practical framework:

1. Start with your condition. If your primary goal is type 2 diabetes control, the drugs approved for diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus, Byetta, Bydureon) are the on-label options. If your goal is weight loss, look at Wegovy, Zepbound, Saxenda, or Foundayo. Several drugs are approved for multiple indications — Wegovy and Zepbound have additional cardiovascular and OSA approvals.
2. Consider potency vs. dosing convenience. Tirzepatide (Mounjaro, Zepbound) currently delivers the largest weight loss in trials. Semaglutide (Ozempic, Wegovy) has the longest cardiovascular outcomes evidence. Oral options trade some potency for the convenience of a tablet.
3. Check coverage before you fall in love with a drug. Insurance coverage for weight-management indications varies dramatically by plan. A drug your plan covers is often a better practical choice than a marginally more effective drug it does not.
4. Work with a clinician. Contraindications (medullary thyroid carcinoma family history, MEN 2, prior pancreatitis) matter, and so do drug-drug interactions and individual tolerability. These drugs are genuinely effective; they are also genuine medications with real risks.

For drug-by-drug detail see the full drug index. For weight-loss-specific rankings, see best GLP-1 for weight loss. For diabetes-specific rankings, see best GLP-1 for diabetes.

Frequently Asked Questions

Are GLP-1 medications safe?

The GLP-1 class has more than two decades of clinical data (exenatide was approved in 2005). Long-term safety is reasonably well characterized. Common side effects are gastrointestinal and usually mild; serious adverse events are rare. The class carries a boxed warning for thyroid C-cell tumors based on rodent studies, though a causal link has not been established in humans.

Do GLP-1 drugs work for people without diabetes?

Yes. Wegovy, Zepbound, Saxenda, and Foundayo are FDA-approved specifically for weight management in adults without diabetes who meet BMI criteria. The STEP and SURMOUNT clinical programs enrolled participants without diabetes.

Do you have to take a GLP-1 forever?

Clinical data on stopping is limited but consistent: most patients who discontinue a GLP-1 regain a substantial portion of lost weight within a year. Long-term use is the assumption behind how these drugs are labeled and studied, though individual clinical judgment varies.

How much weight can you lose on a GLP-1?

Average weight loss in pivotal trials ranges from about 3% (Trulicity, Victoza at their diabetes-labeled doses) to about 22.5% (Zepbound at 15 mg weekly in SURMOUNT-1). Individual responses vary widely — some trial participants lose 25%+, others lose much less.

What is the difference between Ozempic and Wegovy?

Both are semaglutide, from the same manufacturer. Ozempic is FDA-approved for type 2 diabetes at weekly doses up to 2 mg. Wegovy is approved for chronic weight management at weekly doses up to 2.4 mg (injectable) or 7.2 mg (Wegovy HD). Same active ingredient, different dose ceilings, different approved indications. See Ozempic vs Wegovy for the full breakdown.

Are compounded GLP-1s the same as the brand-name versions?

No. Compounded versions are not FDA-approved and have not been tested in the clinical trials that establish efficacy, safety, and dosing. The FDA has taken enforcement action against several compounders. Compounded products should not be considered equivalent to FDA-approved Ozempic, Wegovy, Mounjaro, or Zepbound.